Portuguese genetic testing firm CGC Genetics recently launched a Diabetes/Obesity Mutation Panel that it claims can be used for preventive purposes.
CGC Genetics, a clinical genetics testing company, recently introduced a panel for skeletal dysplasias.
The assay runs on Illumina's digital microbead-based BeadXpress system, and bolsters the Porto, Portugal-based company's menu of Array CGC tests.
The Portugal-based testing company is one of a handful of firms to adopt the holographic microbead-based platform since the US Food and Drug Administration cleared the BeadXpress earlier this year.
Exiqon's Mircury LNA MicroRNA Arrays, CGC Genetics' Prenatal Diagnostic Test
CGC Genetics' Congenital Deafness Panel, EMD Millipore's CpGenome Turbo Kit
Oxford Gene Technology's CytoSure ISCA UPD 4 x 180K Array; CGC Genetics' Microarray Panels for the Diagnosis of Bardet-Biedl Syndrome, Thrombophilia, and Warfarin Pharmacogenetics
The Portuguese genetic testing company has located its US headquarters in Newark, NJ, and it has partnered with New Jersey Medical School's Institute of Genomic Medicine.
The Portuguese lab firm received its CLIA license less than a year after being among a handful of firms to receive a warning notice from California regulators.
A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.
Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.
Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.
In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.